5-Methylmellein and nectriapyrone, two new monoamine oxidase inhibitors

Medical Science Research

Volumn 27, Issue 7, 1999, Pages 463-465

  Lee, In Kyoung ^a   Yun, Bong Sik ^a   Oh, Scikwan ^b   Kim, Young Ho ^c   Lee, Myung Koo ^a   Yoo, Ick Dong ^b  

^a Korea Research Institute of Bioscience and Biotechnology (KRIBB)   (South Korea)

^b Chungnam National University   (South Korea)

^c Chungbuk National University   (South Korea)

Author keywords

5 methylmellein; Fungi; Monoamine oxidase nectriapyrone; Phytotoxin

Indexed keywords

5 METHYLMELLEIN; AMINE OXIDASE (FLAVIN CONTAINING); MONOAMINE OXIDASE INHIBITOR; NECTRIAPYRONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG ISOLATION; DRUG STRUCTURE; ENZYME INHIBITION; FUNGUS; MALE; MOUSE; NONHUMAN;

EID: 0032770319     PISSN: 02698951     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Kopin U. Catecholamine metabolism: Basic aspects and clinical significance. Pharmacol Rev 1985; 37:338-364.
2. Schildkraut JJ. The catecholamine hypothesis of affective disorders; A review of supporting evidence Am J Psychiat 1965; 122:509-522.
3. Cesura AM, Kettler R, Imhof R, DaPrada M. Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide. Psychopharmacology 1992; 106:15.
4. Birkmayer W, Birkmayer G. Strategy and tactic of modern Parkinson therapy. Acta Neural Scand (Suppl) 1989; 126:63-66.
5. Fedelman RS, Meyer JS, Quenzer LF. Principle of Neuropsychopharmacology Sinauer Associates; 1997. pp. 819-838.
6. Okuno T, Oikawa S, Goto T, Sawai K, Shirahama H, Matsumoto T. Structures and phytotoxicity of metabolites from Valsa ceratosperma. Agric Biol Chem 1986; 50:997-1001.
7. Avent AG, Hanson JR, Truneh A. The biosynthesis of nectriapyrone and vermopyrone. Phytochemistry 1992; 31:3447-3449.
8. Naoi M, Nomura Y, Ishiki R, Suzuki H, Nagatsu T. 4-(O-Benzylphenoxy)-N-methylbutylamine (bifemelane) and other 4-(O-benzylphenoxy)-N-methylalkylamines as new inhibitors of type B monoamine oxidase. J Neumchem 1988; 50:243-247.
9. Krajl M. A rapid microfluorimetric determination of monoamine oxidase. Biochem Pharmacol 1965; 14:1683-1685.
10. Turner WB. Aldridge DC. Fungal metabolites II. London: Academic Press; 1983. pp. 87-90.
11. Bemenek ME. Abell CW, Chrisey LA, Rozwadowska MD. Gessner W, Brossi A. Inhibition of monoamine oxidase A and B by simple isoquinolines alkaloids: racemic and optically active 1,2,3,4-tetrahydro3,4-dihydro- and fully aromatic isoquinolines. J Med Chem 1990; 33:147-152.
12. Strolin-Benedetti M, Dosiert PL. Overview of the present MAO inhibitors. J Neural Transm (Suppl) 1987: 23:103-119.
13. Mazouz F, Gueddari S, Burstein C, Mansuy D, Milcent R. 5-(4-benzoyloxyphenyl)-l,3,4-oxadiazol-2(3H)-one derivatives and related analogues: new reversible, highly potent, and selective tnonoamine oxidase type B inhibitors. J Med Chem 1993; 36:1157-1167.
14. White HL, Scales P. Mechanism of monoamine oxidase-A inhibition by BW 1370U87. Drug Dev Res 1992; 25:191-199.
15. Suzuki O, KatsumataY, Oya M, Chari VM, Vermes B.Wagner H, étal. Inhibition of type A and type B monoamine oxidase by naturally occurring xanthones. Planta Med 1981; 42:17-21.
16. Thull U, Testa B. Screening of unsubstituted cyclic compounds as inhibitors of monoamine oxidases. Biochem Pharmacol 1994; 47:2307-2310.
17. Severina IS. Monoamine oxidase; structure, function, and altered functions. New York: Academic Press: 1979. pp. 169-183.